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ADAMTSs (A disintegrin and metalloprotease domains with thrombospondins motifs) are complex extracellular
proteases that have been related to both oncogenic and tumor-protective functions. These enzymes can be
secreted by cancer and stromal cells and may contribute to modify the tumor microenvironment by multiple
mechanisms. Thus, ADAMTSs can cleave or interact with a wide range of extracellular matrix components or
regulatory factors, and therefore affect cell adhesion, migration, proliferation and angiogenesis. The balance of
protumor versusantitumor effects ofADAMTSsmaydependon thenatureof their substratesor interacting-partners
upon secretion from the cell. Moreover, different ADAMTS genes have been found overexpressed, mutated or
epigenetically silenced in tumors from different origins, suggesting the direct impact of these metalloproteases in
cancer development. However, despite the important advances on the tumor biology of ADAMTSs in recent years,
more mechanistic and functional studies are necessary to fully understand how these proteases can influence
tumormicroenvironment to potentiate cancer growth or to induce tumor regression. This reviewoutlines current and
emerging connections between ADAMTSs and cancer.
© 2015 Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
In 1997, Kuno et al. reported the identification and
cloning of a new ADAM (A Disintegrin AndMetallopro-
teinase domains) metalloprotease in a cell model of
colon cancer cachexia [1]. This enzyme was named
ADAMTS-1 (A Disintegrin And Metalloproteinase with
ThromboSpondin motifs) to remark the presence of
three thrombospondin type-1 (TS1) motifs within its
structure. The first TS1 motif was located in the middle
region of the amino acid sequence of this enzyme, and
the remaining two were situated in tandem at the
carboxy-terminal region of the protein. Another impor-
tant differencewith respect to the classical ADAMswas
the finding that ADAMTS-1 was a secreted enzyme
lacking the transmembrane domain placed at the
carboxy-terminal end of the membrane-anchored
ADAMs. Both ADAMs and the closely related MMPsblished by Elsevier B.V. This is an
rg/licenses/by-nc-nd/4.0/).were metalloproteases largely associated with tumor-
igenesis [2], therefore it was proposed that ADAMTS-1
could also influence tumor growth through modulation
of cell proliferation, migration, inflammation and angio-
genesis processes.
The discovery of ADAMTS-1 encouraged the search
for new ADAMTS genes. The availability of the first
draft of the human genome sequence and the efforts of
different laboratories allowed to complete themolecular
cloning of the 19 human ADAMTSs in 2003 [3,4]. Each
newly identified ADAMTS displayed a domain organi-
zation similar to that shown by ADAMTS-1, character-
ized by the presence of a central TS1 motif and a
variable number of TS1 repeats at the carboxy-terminal
region, as well as the absence of a transmembrane
domain. In addition, other ancillary domains described
in ADAMTSsbut not in ADAMswere the spacer region,
located after a cysteine-rich region in all ADAMTSs; aopen access article under the CC BY-NC-ND license




















































Fig. 1. Schematic representation of the antitumor effects mediated by ADAMTS metalloproteases. These effects have
been mainly described for ADAMTS-1. ADAMTSs can be produced by stromal or tumor cells, and exert antitumor
properties inhibiting angiogenic or lymphangiogenic processes, or blocking tumor-promoting signaling pathways in tumor
cells. These effects may be both dependent (degradation of extracellular components such as thrombospondin-1 and -2,
and nidogen-1 and -2), or independent (VEGF sequestration) of the catalytic activity. Several ADAMTS genes are silenced
through epigenetic modification in tumors from different origins. Structural domains of ADAMTSs are indicated.
78 ADAMTS proteases and cancerspacer-2 region between the fourth and fifth TS1motifs
in ADAMTS-7 andADAMTS-12; theGON-1 domain at
the carboxy-terminal end of ADAMTS-9 and
ADAMTS-20; the PLAC domain in ADAMTS-2, -3,
-6, -7, -10, -12, -14, -15, -16, -17 and -19; and the CUB
domains in ADAMTS-13 [5]. These structural domains
could influence protease activity and led to considerADAMTSs as a new family of secreted metallopro-
teases [6–8]. Phylogenetic analysis of the 19 human
ADAMTSs allowed their classification into different
subfamilies of closely related members [4,5].
Functional characterization of different ADAMTSs
revealed that they were involved in key biological




























Fig. 2. Schematic representation of the protumor effects mediated by ADAMTSmetalloproteases. ADAMTSs may cleave
or induce the release or activation of pro-angiogenic factors (HB-EGF, amphiregulin, IGFBP2), and digest extracellular matrix
components (proteoglycans) to facilitate tumor cell spreading and metastasis. Protumor effects elicited by ADAMTSs are
protease-dependent. Additionally, ADAMTSs can induce the recruitment of fibroblasts involved in tumor growth. Genetic
alterations of ADAMTS genes can also induce protumor effects. Structural domains of ADAMTSs are indicated.
79ADAMTS proteases and cancerADAMTS-14 are procollagen N-proteinases [9–11],
and loss-of-function mutations in ADAMTS2 cause
Ehlers–Danlos syndrome VIIC, a connective tissue
disorder characterized by severe skin fragility [12].
ADAMTS-4 and ADAMTS-5/11 are responsible for
aggrecan degradation in osteoarthritic diseases
[13,14]. ADAMTS10 mutations underlie Weill–
Marchesani syndrome [15], an acromelic dysplasia
associated with short stature, eye abnormalities,
brachydactyly and joint stiffness. A Weill–Marchesani-
like syndrome is caused by mutations in theADAMTS17 gene [16]. In this case, affected individuals
exhibit some of the symptoms of Weill–Marchesani
syndrome, but they show no signs of brachydactyly or
decreased joint flexibility. ADAMTS-13 is the enzyme
responsible for the cleavage of large multimers of von
Willebrand factor [17], anddefects in thegeneencoding
this metalloprotease cause thrombotic thrombocytope-
nic purpura, a life-threatening hematologic disease
characterized by the inability of blood to clot normally
[18]. Adamts20 is mutated in belted mice, which lack
pigment in thebelt-like regionof the trunkasa result of a
80 ADAMTS proteases and cancerdefect in melanocyte development [19]. These exam-
ples illustrate the functional relevance of ADAMTSs not
only in normal biological events but also in pathological
conditions.
ADAMTSs have also been associated with cancer
as their expression was found to be altered in tumors
from different origins, similarly to what happened
with the founder member of the family ADAMTS-1 in
colon cancer cachexia [8]. However a growing
number of studies have also highlighted the tumor-
protective effects of ADAMTSs [20,21]. Different
mechanisms have been linked to the protumor or
antitumor activities of these metalloproteases,
including regulation of angiogenesis, cell prolifera-
tion, adhesion andmigration, as well as degradation
or interaction with extracellular matrix components.
Moreover, several ADAMTS genes have been
found mutated or epigenetically silenced in specific
tumors. In this review, we summarize the tumor
suppressive effects and the oncogenic functions
elicited by ADAMTS metalloproteases.Tumor-protective effects of ADAMTSs
Following its identification in a mouse colon cancer
cachexia tumor cell line [1], ADAMTS-1orMETH-1was
described as an angio-inhibitory enzyme due to its
capacity to restrain endothelial cell proliferation. The
carboxy-terminal half region of the enzyme, comprising
the TS1 motifs, is responsible for this inhibitory effect,
which occurs by sequestration of VEGF165 [22,23].
TheADAMTS-1 catalytic domain is not directly required
to elicit anti-angiogenic effects in different tumor cell
lines [24]. However, ADAMTS-1 proteolytic activity
mediates the release of angio-inhibitory polypeptides
from thrombospondin-1 and -2 [25]. Thus, fragments
generated through proteolytic cleavage of thrombos-
pondin-1 by ADAMTS-1 suppress vascularization
of liver metastasis [26]. Nonetheless, overexpression
of thrombospondin-1 does not affect vascularization of
lung metastasis, an organ that exhibits low ADAMTS-1
activity [26]. In addition, it has also been recently shown
that ADAMTS-1 is responsible for the degradation of
nidogen-1 and -2 in a mouse model of breast cancer,
which contributes to enhance the anti-angiogenic
response by the metalloprotease [27]. Angio-inhibitory
effects, using cell-based assays or animal models,
have also been associated with other ADAMTSs
including ADAMTS-2 [28], ADAMTS-4 [29],
ADAMTS-5 [30,31], ADAMTS-8 or METH-2 [22,32],
ADAMTS-9 [33,34], and ADAMTS-12 [35]. Neverthe-
less, different mechanisms seem to underlie these
angio-inhibitory capacities. For instance and similarly
to ADAMTS-1, ADAMTS-2 [28], ADAMTS-5 [30,31]
and ADAMTS-12 [36] do not require their catalytic
activity to block angiogenesis, an effect most likely
related to the TS1 motifs. By contrast, proteolytic
activity of ADAMTS-9 [34] and ADAMTS-15 [37] areessential to promote angio-inhibitory capacity. Contrary
to ADAMTS-1, ADAMTS-9 does not cleave thrombos-
pondins 1 and 2 and does not bind VEGF165 [34].
However, ADAMTS-4 is also able to capture and
inactivate VEGF and, additionally, to inhibit phosphor-
ylation of VEGF receptor 2 (VEGFR2) [29]. An early
report by Iruela-Arispe et al. showed that ADAMTS-1
can also inactivate VEGFR2 in human aortic endothe-
lial cells [38]. More recently it has also been found that
ADAMTS-1 is able to block VEGFR3 phosphorylation
in human dermal lymphatic microvascular endothelial
cells HMVEC-dLy, leading to an inhibition of lymphan-
giogenesis [39]. These findings point out the impor-
tance of ADAMTSs as modulators of both angiogenic
and lymphangiogenic responses (Fig. 1).
Different ADAMTSs may exert their antitumor
effects through the blocking of Erk phosphorylation,
a signaling pathway usually increased in tumor cells
[40]. This inhibitory effect was initially described for
the Xenopus ortholog of ADAMTS-1 [41]. Further-
more, and consistent with ADAMTS angio-inhibitory
capacities, it has been shown that ADAMTS-2
decreases Erk phosphorylation levels in HUVEC
cells but not in fibroblasts [28], and that ADAMTS-12
inhibits Erk phosphorylation and tubulogenesis in
MDCK cells upon stimulation with hepatocyte growth
factor [36]. Abrogation of Erk phosphorylation has also
been linked to ectopic expression of ADAMTS-15 in
colon cancer cells [42], and ADAMTS-8 in epithelial
and esophageal carcinoma cells [43]. However, levels
of Erk phosphorylation remain unaltered when
ADAMTS-9 is exogenously expressed in gastric
cancer cells, whereas levels of phosphorylated Akt
and phospho-mTOR are reduced [44]. These findings
indicate that ADAMTSs may modulate different
cancer-related signaling pathways. Functional conse-
quences of the ectopic expression of these ADAMTSs
were analyzed using different cell-based models,
including wound-healing, cell proliferation, and tumor
formation in nude mice. For instance, ADAMTS-1
inhibits tumor growth when human fibrosarcoma
HT-1080, humanprostate cancerDU-145 andChinese
hamster ovary CHO-K1 cells are subcutaneously
inoculated in mice [24]. Likewise, the presence of
ADAMTS-15 in mammary cancer cells decreases cell
migration on extracellular matrix components such as
fibronectin or laminin [37]. Conversely, knock-down of
ADAMTS-1, ADAMTS-9 and ADAMTS-15 increases
the tumorigenic potential of breast, gastric and colon
cancer cells [42,44,45]. Moreover, reduction of
ADAMTS-9 expression using RNA interference in
a nontumorigenic HONE1 epithelial cell line causes
the restoration of a tumorigenic phenotype [33]. In
this regard, ADAMTS-13 deficiency has been
related to neoplasia-associated microangiopathic
hemolytic anemia in colon cancer patients [46].
These studies indicate that loss-of-function of
ADAMTSmetalloproteasesmay contribute to increase
tumor cell malignancy.
81ADAMTS proteases and cancerAntitumor effects of ADAMTSs can also be inferred
by the fact that several ADAMTS genes have been
found epigenetically silenced in tumors from different
origins (Fig. 1). Thus, ADAMTS1 shows high frequen-
cy of promoter methylation in pancreatic, colorectal
and lung cancer [47–49]; ADAMTS5 in colorectal
cancer [50]; ADAMTS8 in brain; thyroid, lung, naso-
pharyngeal, esophageal, gastric and colorectal can-
cers [32,43,51,52]; ADAMTS9 in esophageal,
nasopharyngeal, gastric, colorectal and pancreatic
cancers [33,44,53,54], as well as in multiple myeloma
[55]; ADAMTS12 in colon cancer [56], and ADAMT18
in gastric, colorectal, pancreatic, esophageal and
nasopharyngeal carcinomas [57,58]. It is noteworthy
that some ADAMTSs can be also found expressed in
stromal cells but not in cancer cells [59]. This is the
case of ADAMTS-12, which has been detected in
cancer-associated fibroblasts but not in tumor cells
in colon carcinoma samples [56]. The presence of
this metalloprotease has been related to a stromal
response aimed to control tumor progression, thereby
ADAMTS-12 has emerged as a potential marker of
good prognosis in this type of tumor [56,60]. Con-
versely, ADAMTS-15 is detected in colon cancer cells
rather than in stromal cells, and its expression
inversely correlates with the histopathological grade
of tumors [42]. Notably, ADAMTS15 gene is not
epigenetically silenced, but it has been found frequently
mutated not only in colon but also in pancreatic
carcinomas [42,61,62]. Tumor-suppressive effects
elicited by ADAMTS-15 have also been described in
breast carcinomas and its detection is associated
with a better clinical outcome in breast cancer
patients [59,63]. Nevertheless, additional studies
would be necessary to determine whether ADAMTS
genes are frequently mutated in tumors, as well as to
evaluate the functional implications of thesemutations
in cancer development. Data available at COSMIC
database (cancer.sanger.ac.uk) suggest that indeed,
distinctADAMTS genes can begenetically inactivated
in different types of tumors.Protumor effects of ADAMTSs
ADAMTS-1 is the best characterized tumor-
promoting ADAMTS metalloprotease. In fact, shortly
after its discovery, ADAMTS-1 was found overex-
pressed in pancreatic cancer and proposed to be
involved in tumor progression facilitating local invasion
and lymph node metastasis [64]. Also, recent studies
showed that ADAMTS1 overexpression in a fibrosar-
coma model increased tumor growth rate that was
angiogenesis independent [65]. Furthermore, in conflict
with the angio-inhibitory effect derived from the
proteolytic cleavage of thrombospondin-1, the enzy-
matic activity of ADAMTS-1 is required to enhance
angiogenesis and to promote pulmonary metastasis of
both Lewis lung carcinoma and TA3 murine mammarycarcinoma cells [66]. These processes are accompa-
nied by the shedding of heparin-binding epidermal
growth factor (HB-EGF) and amphiregulin, and the
activation of epidermal growth factor receptor (EGFR)
(Fig. 2). By contrast, the overexpression of a catalyt-
ically inactiveADAMTS-1 impedes these events, which
strongly suggests a prometastatic role for this metallo-
protease mediated by its proteolytic activity [66].
Elevated ADAMTS-1 expression has also been asso-
ciatedwith high risk of bonemetastasis in breast cancer
patients [67,68].
Further studies using animal models have provided
additional support to the proposed protumor effects of
ADAMTS-1 in mammary carcinomas. In fact, both
growth of mammary tumors and lung metastasis are
reduced in Adamts1-deficient mice compared to
wild-type mice using the MMTV-PyMT mouse mam-
mary tumor model [69]. Notably, a high accumulation
of cleaved versican is found in the tumor microenvi-
ronment in wild-type mice, but not in knock-out mice.
Thus, it has been proposed that ADAMTS-1 could
facilitate the spreading of tumor cells through the
degradation of versican, a predictor of metastatic
relapse in human breast cancer [70]. In addition, it has
been reported that metastasis of breast cancer cells
can be promoted by the ADAMTS-1 mediated
cleavage of the extracellular matrix component
semaphorin 3C [71]. ADAMTS-1 catalytic activity is
also involved in a stromal response to recruit
fibroblasts, thus promoting lung cancer tumor growth
[8]. Moreover, breast tissue-associated fibroblasts
also contribute topromote cancer cell invasion through
up-regulation of ADAMTS-1 levels (Fig. 2) [72].
Furthermore, ADAMTS-1 may associate its proteolytic
action with MMP-1 activity to promote osteolytic bone
metastasis by shedding of different membrane-bound
epithelial growth factor (EGF-like) factors [68]. Recent-
ly, insulin-like growth factor binding protein-2 (IGFBP2)
has also been identified as a target of ADAMTS-1, and
a high expression of the metalloprotease correlates
with higher levels of cleaved IGFBP2 in glioblastoma
[27]. It is noteworthy that ADAMTS-1 proteolytic activity
can be increased by the interaction with fibulin-1, a
secreted glycoprotein that also displays protumor and
antitumor effects [73,74]. In turn, fibulin-1 can interact
with different extracellular matrix components including
known ADAMTS-1 substrates such as nidogen-1 and
versican [75]. Consequently, fibulin-1 could play a
crucial role in the balance of protumor effects versus
tumor-protective functions displayed by ADAMTS-1. In
any case, these studies support the influence of
ADAMTS-1 catalytic activity in the remodeling of the
tumor microenvironment to facilitate the spreading of
tumor cells in different types of cancer [76].
ADAMTS-4 and ADAMTS-5 are proteoglycanases
that can contribute to increase the invasive potential
of glioblastoma cancer cells through the degradation
of brevican (Fig. 2), a highly expressed proteoglycan
in this type of malignant brain tumor [77,78]. Notably,
82 ADAMTS proteases and cancera mutant form of brevican resistant to ADAMTS
cleavage does not enhance glioma cell invasion,
highlighting the importance of the proteolytic pro-
cessing of brevican mediated by ADAMTS in the
invasiveness of tumor cells [79]. Furthermore, the
N-terminal cleavage product of brevican binds to
fibronectin and increases glioma cell dispersion [80].
The presence of high levels of ADAMTS-4 has also
been linked to an increase of tumorigenic potential in
head and neck squamous cell carcinomas [81], and
in Ewing's sarcomas, where this metalloprotease
has emerged as a potential tumor marker [82]. It is
noteworthy that ADAMTS-4 undergoes an autocatalyt-
ic processing similar to that described for ADAMTS-1,
which affects balance between protumorigenic and
antitumorigenic functions of this metalloprotease [83].
Thus, an N-terminal 53-kDa catalytically active
isoform of the enzyme promotes B16 melanoma
angiogenesis in mice. In clear contrast, the catalyt-
ically inactive full-length protein or different truncated
fragments containing C-terminal ancillary domains
impede melanoma cell growth and angiogenesis
process. In reference to ADAMTS-5, this is the main
aggrecanasedetected in laryngeal carcinomas and its
catalytic activity may contribute to facilitate dissemi-
nation of tumor cells [84].
Protumor activities have also been reported for
ADAMTS-12. Thus, this metalloprotease can poten-
tiate trophoblast invasion by a mechanism involving
αvβ3 integrin [85]. In a recent report, it has also been
shown that ADAMTS-12 potentiates migration of
MCF-7 breast cancer cells when is expressed in
absence of fibulin-2 [86]. Interestingly, ADAMTS-12
is able to interact with fibulin-2 and a concomitant
expression of both extracellular proteins consider-
ably reduces protumor capacities of breast tumor
cells [86]. Furthermore, combined high expression of
both ADAMTS-12 and fibulin-2 correlates with the
best prognosis in breast cancer patients. Fibulin-2,
similarly to fibulin-1, may act as a protumor or
antitumor glycoprotein [74,87]. For instance, fibulin-2
drives malignant lung cancer progression [88], but
reduces breast cancer cell invasion [89]. There-
fore, fibulin-2 could act as a modulator between
tumor-promoting and anti-oncogenic roles associ-
ated to ADAMTS-12.
Other ADAMTS metalloproteases showing tumor-
associated effects are ADAMTS-2, which is upregulat-
ed in osteosarcoma cells following treatment with
TGF-β [90]; ADAMTS-14, which is part of an expres-
sion signature involved in the generation of experimen-
tal bone metastasis by IGR-CaP1 human prostate
cancer cells [91]; and ADAMTS-18, which is the
ADAMTS metalloprotease most frequently mutated
in melanoma and some of these mutations promote
cancer growth and metastasis of melanoma cells [92].
Overall, these findings illustrate the very different and
complex protumor actions that may be elicited by the
ADAMTS metalloproteases.Conclusions and future directions
Alteration of the tumor microenvironment is es-
sential to promote cancer growth and metastasis.
Secreted or membrane-associated metalloprotease
activities have been traditionally associated with an
increase of the tumorigenic potential of tumor cells.
However, a growing number of studies support the
tumor-suppressive role of different metalloproteases
[93]. In relation to ADAMTSs, these enzymes can be
secreted by tumor or stromal cells and then modify
the primary tumor microenvironment by proteolytic-
dependent or independent mechanisms. Thus, it
could be speculated that pro-tumor functions or anti-
oncogenic properties elicited by the ADAMTSs may
depend on the substrates or interacting-partners
present in the cell microenvironment. A future
challenge would be to differentiate the nature of
ADAMTS-mediated interactions and processing
events of regulatory growth factors or extracellular
matrix components that potentiate tumor growth from
those that suppress metastasis. Additionally, a more
profound knowledge of the molecular mechanisms
regulated by ADAMTSs would contribute to better
understand the real impact of these metalloproteases
in tumorigenesis. Hopefully, clarification of these
processes will help to introduce more specific and
less toxic personalized antitumor therapies.Acknowledgments
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